The in Vivo Performance of Plasmonic Nanobubbles As Cell Theranostic Agents in Zebrafish Hosting Prostate Cancer Xenografts
Overview
Authors
Affiliations
Cell theranostics is a new approach that unites diagnosis, therapy and confirmation (guidance) of the results of therapy in one single process at cell level, thus principally improving both the rapidity and precision of treatment. The ideal theranostic agent will support all three of the above functions in vivo with cellular resolution, allowing individual assessment of disease state and the elimination of diseased cells while leaving healthy cells intact. We have developed and evaluated plasmonic nanobubbles (PNBs) as an in vivo tunable theranostic cellular agent in zebrafish hosting prostate cancer xenografts. PNBs were selectively generated around gold nanoparticles in cancer cells in the zebrafish with short single laser pulses. By varying the energy of the laser pulse, we dynamically tuned the PNB size in a theranostic sequence of two PNBs: an initial small PNB detected a cancer cell through optical scattering, followed by a second bigger PNB, which mechanically ablated this cell without damage to surrounding tissue, while its optical scattering confirmed the destruction of the cell. Thus PNBs supported the diagnosis and guided ablation of individual human cancer cells in a living organism without damage to the host.
Enhanced Nanobubble Formation: Gold Nanoparticle Conjugation to Qβ Virus-like Particles.
Parsamian P, Liu Y, Xie C, Chen Z, Kang P, Wijesundara Y ACS Nano. 2023; 17(8):7797-7805.
PMID: 36884260 PMC: 10461784. DOI: 10.1021/acsnano.3c00638.
Modeling of Solid-Tumor Microenvironment in Zebrafish (Danio Rerio) Larvae.
Yao Y, Wang L, Wang X Adv Exp Med Biol. 2020; 1219:413-428.
PMID: 32130712 DOI: 10.1007/978-3-030-34025-4_22.
A Preclinical Embryonic Zebrafish Xenograft Model to Investigate CAR T Cells In Vivo.
Pascoal S, Salzer B, Scheuringer E, Wenninger-Weinzierl A, Sturtzel C, Holter W Cancers (Basel). 2020; 12(3).
PMID: 32121414 PMC: 7139560. DOI: 10.3390/cancers12030567.
Witzigmann D, Uhl P, Sieber S, Kaufman C, Einfalt T, Schoneweis K Elife. 2019; 8.
PMID: 31333191 PMC: 6682401. DOI: 10.7554/eLife.42276.
Wu X, Yue G, Dong J, Lam C, Wong C, Qiu M Front Pharmacol. 2019; 9:1466.
PMID: 30618758 PMC: 6299023. DOI: 10.3389/fphar.2018.01466.